Welcome to our dedicated page for iRhythm Holdings SEC filings (Ticker: IRTC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The iRhythm Technologies, Inc. (NASDAQ: IRTC) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a public issuer. As a digital health care company focused on ambulatory cardiac monitoring and data analytics, iRhythm uses its SEC reports to communicate financial performance, risk factors, governance matters, and material corporate events related to its Zio long-term continuous monitoring (LTCM) service and broader operations.
Investors can use this page to review current and historical filings retrieved from the SEC’s EDGAR system, including annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K. Recent 8-K filings have covered topics such as quarterly financial results, investor presentations, and amendments to the Executive Change in Control and Severance Policy, which outlines severance payments, COBRA coverage, and equity vesting treatment for senior leaders under specified termination scenarios.
For those analyzing iRhythm’s business in more depth, the company’s periodic reports typically discuss revenue from Zio services, gross margins, operating expenses, non-GAAP measures like adjusted EBITDA and adjusted net loss, and liquidity metrics such as cash, cash equivalents, and marketable securities. These documents also describe how iRhythm accounts for items like stock-based compensation, business transformation costs, and other adjustments that affect non-GAAP results.
Stock Titan enhances access to these filings with AI-powered summaries that help explain the key points of lengthy documents, such as 10-K and 10-Q reports, in more accessible language. Users can quickly identify major changes in financial condition, updates to risk disclosures, and details of insider or executive-related arrangements that appear in forms and exhibits. This combination of real-time filing access and AI-generated insights can support investors, analysts, and other stakeholders who want to understand how iRhythm reports on its digital cardiac monitoring business and corporate governance over time.
iRhythm Holdings, Inc. received an amended Schedule 13G/A from Artisan-affiliated investment entities reporting their ownership of the company’s common stock. As of the reported date, these entities beneficially own 1,511,992 shares, representing 4.7% of the outstanding common stock, based on 32,219,143 shares outstanding as of October 23, 2025.
The Artisan entities report no sole voting or dispositive power over iRhythm shares, but shared voting power over 1,314,008 shares and shared dispositive power over 1,511,992 shares. They certify the position is held in the ordinary course of business and not for the purpose of changing or influencing control of iRhythm.
iRhythm Technologies, Inc. filed a Form 15 to end its own registration and reporting obligations after implementing a new holding company structure under Delaware law. In this transaction, iRhythm merged into a wholly owned subsidiary of iRhythm Holdings, Inc., with iRhythm surviving as a subsidiary.
At the effective time, each share of iRhythm common stock was automatically converted into one share of iRhythm Holdings common stock, with the same rights and preferences. The transaction is treated as a succession under Rule 12g-3(a), so iRhythm Holdings continues as the Exchange Act reporting company.
iRhythm Technologies, Inc. (IRTC) furnished an investor presentation as part of its shareholder engagement program. The presentation is included as Exhibit 99.1 to the report.
The materials in this disclosure are provided under Item 7.01 (Regulation FD) and are expressly stated as “furnished,” not “filed,” which means they are not subject to Section 18 liability and are not incorporated into other Securities Act or Exchange Act filings except by specific reference.
iRhythm Technologies (IRTC) reported an insider transaction by its President and CEO, who is also a Director. On 11/03/2025, the officer sold 14,059 shares of common stock at a price of $182.9367 per share.
The filing states the shares were sold to cover tax withholding and remittance obligations related to the vesting of Restricted Stock Units. Following the sale, the officer beneficially owns 164,979 shares, held directly.
iRhythm Technologies (IRTC) reported an insider transaction on Form 4. The company’s Chief Financial Officer sold 8,000 shares of common stock at $207.44 on 10/31/2025 pursuant to a Rule 10b5-1 trading plan established on November 14, 2024. Following the sale, the officer beneficially owns 26,470 shares directly and 100 shares indirectly through The Wilson Living Trust.
iRhythm Technologies (IRTC) reported strong top-line growth with narrowed losses. For the three months ended September 30, 2025, revenue was $192.9 million versus $147.5 million a year ago, and gross profit was $137.1 million versus $101.5 million. Loss from operations improved to $8.4 million from $50.3 million, and net loss was $5.2 million compared with $46.2 million. Net loss per share was $0.16 versus $1.48.
Year to date, revenue reached $538.2 million and operating cash flow was $54.7 million. The balance sheet showed cash and cash equivalents of $255.6 million and marketable securities of $309.6 million, with total assets of $995.2 million. Long‑term senior convertible notes stood at $648.8 million (carrying amount). Operating expenses reflected continued investment, including $21.0 million in R&D and $124.2 million in SG&A for the quarter. Shares outstanding were 32,219,143 as of October 23, 2025.
iRhythm Technologies (IRTC) furnished third‑quarter results and updated its executive severance program. The company furnished a press release for the quarter ended September 30, 2025 as Exhibit 99.1, noting it is furnished, not filed. The Board approved an amended and restated Executive Change in Control and Severance Policy covering Vice Presidents and above, including the CEO and other named officers.
Outside a change‑in‑control period, the CEO is eligible for 18 months of base salary, a 150% target bonus amount, and 18 months of COBRA; the CFO, Chief People Officer, and EVPs receive 12 months salary, 100% target bonus, and 12 months COBRA; SVPs and VPs receive 6 months salary, 50% target bonus, and 6 months COBRA. During the change‑in‑control period, the CEO terms increase to 24 months salary, 200% target bonus, 24 months COBRA, plus 100% acceleration of time‑based equity; CFO/Chief People Officer/EVPs: 18 months salary, 150% target bonus, 15 months COBRA, 100% equity acceleration; SVPs/VPs: 9 months salary, 75% target bonus, 9 months COBRA, 100% equity acceleration.
Daniel G. Wilson, Chief Financial Officer of iRhythm Technologies (IRTC), reported a sale of common stock executed under a Rule 10b5-1 trading plan. On 09/03/2025 Mr. Wilson disposed of 5,000 shares at $175 per share. After this transaction he beneficially owned 34,470 shares directly and an additional 100 shares indirectly through The Wilson Living Trust dated July 9, 2015, of which he is Trustee. The Form 4 was signed by an attorney-in-fact on 09/04/2025 and notes the 10b5-1 plan was established November 14, 2024.
Daniel G. Wilson, Chief Financial Officer of iRhythm Technologies, Inc. (IRTC), reported a sale of 737 shares of common stock on 09/02/2025 at a price of $167.28 per share. The filing states the shares were sold to cover tax withholding and remittance obligations related to the vesting of restricted stock units (RSUs). After the sale, Mr. Wilson directly beneficially owned 39,470 shares. The filing also discloses an indirect ownership of 100 shares held through The Wilson Living Trust dated July 9, 2015, of which he is trustee. The Form 4 was signed by an attorney-in-fact on 09/03/2025, reflecting a routine, compliance-focused disclosure of an insider transaction tied to RSU vesting.
iRhythm Technologies (IRTC) Form 144 reports a proposed sale of 5,000 common shares to occur on 09/03/2025 through Morgan Stanley Smith Barney LLC on Nasdaq with an aggregate market value of $875,000. The filing shows the 5,000 shares were originally granted as restricted stock in four tranches between 07/01/2020 and 12/31/2023, and the total equals the 5,000 shares listed for sale. The filer previously sold 3,737 shares in the past three months for aggregate proceeds of $573,285.36. The filing includes the required attestation that the seller is not aware of undisclosed material adverse information.
FAQ
What is the current stock price of iRhythm Holdings (IRTC)?
What is the market cap of iRhythm Holdings (IRTC)?
